Introdução: Os nanocarreadores lipídicos são sistemas utilizados para direcionar fármacos especificamente para seu sítio de ação e têm atraído bastante atenção da comunidade científica por serem biocompatíveis e biodegradáveis. Esses sistemas podem direcionar fármacos para os tumores sólidos, possibilitando uma liberação prolongada no sítio de ação e, com isso, ampliando a utilidade da quimioterapia antineoplásica. Objetivo: Revisar a literatura disponível sobre os estudos in vivo envolvendo nanocarreadores lipídicos contendo fármacos citotóxicos, voltados ao tratamento de tumores sólidos. Método: Pesquisa realizada na base de dados PubMed®, no período temporal de 2007 até 2011, utilizando os descritores: liposomes; lipid nanoparticles; cancer; in vivo; com o operador booleano and entre eles, em inglês. Resultados: Foram encontrados 1.595 trabalhos relacionados com o uso de lipossomas e 77 relacionados as nanopartículas lipídicas. Poucos trabalhos tem relatado a avaliação in vivo das nanopartículas lipídicas (28 trabalhos), comparado ao observado para os lipossomas (472 trabalhos), desde que os lipossomas foram desenvolvidos duas décadas antes das nanopartículas lipídicas. Quatro medicamentos com lipossomas já estão aprovados e são utilizados na clínica, ao passo que apenas uma preparação com nanopartículas lipídicas esta sob investigação clínica, em fase I. Conclusão: De forma geral, o número de trabalhos relativos ao uso da nanotecnologia para o tratamento do câncer tem aumentado rapidamente, tornando importante saber diferenciar os diversos tipos de nanocarreadores e, principalmente, conhecer quais já estão em uso na clínica. Existem poucos estudos clínicos com os nanocarreadores lipídicos, entretanto esses sistemas apresentam enorme potencial para melhorar a prática clínica na oncologia.

BACKGROUND: Liver metastases from colorectal cancer are an important public health problem due to the increasing incidence of colorectal cancer worldwide. Synchronous colorectal liver metastasis has been associated with worse survival, but this prognosis is controversial. OBJECTIVE: The objective of this study was to evaluate the recurrence-free survival and overall survival between groups of patients with metachronous and synchronous colorectal hepatic metastasis. METHODS: This was a retrospective analysis of medical records of patients with colorectal liver metastases seen from 2013 to 2016, divided into a metachronous and a synchronous group. The Cox regression model and the Kaplan-Meier method with log-rank test were used to compare survival between groups. RESULTS: The mean recurrence-free survival was 9.75 months and 50% at 1 year in the metachronous group and 19.73 months and 63.3% at 1 year in the synchronous group. The mean overall survival was 20.00 months and 6.2% at 3 years in the metachronous group and 30.39 months and 31.6% at 3 years in the synchronous group. Patients with metachronous hepatic metastasis presented worse overall survival in multivariate analysis. The use of biological drugs combined with chemotherapy was related to the best overall survival prognosis. CONCLUSION: Metachronous colorectal hepatic metastasis was associated with a worse prognosis for overall survival. There was no difference in recurrence-free survival between metachronous and synchronous metastases.

Objective: To verify the prevalence of obesity in patients undergoing cancer follow-up at Hospital das Clínicas in Universidade Federal de Goiás, analyzing the epidemiological and laboratory profile. Methods: Retrospective, analytical and observational study. The final sample consisted of 498 medical records of patients under regular follow-up with indication for chemotherapy between June 2018 and 2020. Anthropometric data, gestational history, personal and family history, menopausal status, comorbidities, staging, and laboratory tests were observed. Results: A mean body mass index of 28.3 kg/m² was found among the patients, and 26.51% were obese. Mean age at diagnosis was 52.79 years, and 51.81% were in menopause. Also, 26.23% had a personal history of breast cancer, and 44.76% had family history. Regarding comorbidities, 51.15% had them, being the most frequent one systemic arterial hypertension, more prevalent in the obese group compared to the normal body mass index. Also, 11.96% of the patients were nulliparous. Regarding staging, most were in T2N0M0 at diagnosis. In laboratory tests, it was found that among patients with breast cancer who had information on lipid profile, low-density lipoprotein and total cholesterol were above the reference limit. Conclusion: 57.63% were obese or overweight, demonstrating body mass index as a risk factor for breast cancer. It was observed that the group of patients with obesity had a statistically significant relationship with the presence of concomitant comorbidities; however, no statistically significant results were found regarding the relationship between body mass index and menopausal status.

recurrence p = 0.018; liver recurrence p = 0.03). There was no difference in the incidence of any or local recurrences between RM1e5mm (p = 0.445) and 5e10mm (p = 0.837). The presence of synchronous disease demonstrated a trend towards liver recurrences only (p = 0.053) but did not reach statistical significance. On multivariate analysis, only R1 affected the incidence of liver recurrence (p = 0.019) but not overall recurrence (p = 0.087). Conclusion: R1 resection is associated with increased recurrence in the liver irrespective of chemotherapy use. There is no difference in recurrence between resection margins1e5mm and 5e10mm.

Resumo Introdução: o Mesotelioma Peritoneal Maligno (MPM) é uma doença rara e letal com variável grau de agressividade. A morbimortalidade está relacionada com a carga de doença tumoral e a sobrevida mediana sem tratamento é de cerca de 12 meses. Quimioterapia baseada em cisplatina é o tratamento padrão nos casos de doença avançada irressecável, ou nos pacientes que declinam cirurgia, associado a quimioterapia hipertérmica intraperitoneal (HIPEC). Desenvolvimento: paciente, 54 anos, com histórico de perda ponderal, desconforto e aumento progressivo de volume abdominal, com imagem evidenciando espessamento peritoneal difuso e ascite, foi submetido a laparoscopia e biópsia com achados positivos para MPM, sendo realizada quimioterapia de 3ª linha com cisplatina e gemcitabine, seguido de manutenção com gemcitabine, apresentando resposta completa, sendo, portanto, caso de resposta excepcional e atípica para doença. Considerações finais: Apesar dos fatores de prognóstico desfavoráveis e rápida progressão aos esquemas iniciais, o paciente do caso apresentou melhora clínica importante e ausência de doença mensurável com esquema de cisplatina e gemcitabine, seguido de gemcitabine de manutenção. Comparado com dados vigentes na literatura, tal resposta é excepcional e atípica, haja vista as características biológicas tumorais da doença. Palavras-chave: Neoplasias Peritoneais; Oncologia; Antineoplásicos Alquilantes; Antimitóticos Abstract Objective: Malignant peritoneal mesothelioma (MPM) is a rare and lethal disease with variable degree of aggressiveness. Morbidity and mortality are related to the burden of tumor disease and median survival without treatment is about 12 months. Cisplatin-based chemotherapy is the standard of treatment in cases of advanced unresectable disease or in patients who decline surgery associated with intraperitoneal hyperthermic chemotherapy (HIPEC). Development: a 54-year-old patient with a history of discomfort, progressive increase in abdominal volume and weight loss, with an image showing diffuse peritoneal thickening and ascites, underwent laparoscopy and biopsy with positive findings for MPM, undergoing 3rd-line chemotherapy with cisplatin and gemcitabine, followed by maintenance with gemcitabine, showing a complete response, therefore being an exceptional and atypical response to disease. Final considerations: Despite the unfavorable prognostic factors and rapid progression to the initial regimens, the patient showed significant clinical improvement and absence of measurable disease with cisplatin and gemcitabine regimen, followed by maintenance gemcitabine. Compared with data from the literature, exceptional and atypical presentation, due to the tumor's biological characteristics of the disease. Keywords: Peritoneal Neoplasms; Medical Oncology; Antineoplastic Agents, Alkylating; Antimitotic Agents